Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT06052475

Physiological Versus Right Ventricular Outcome Trial Evaluated for Bradycardia Treatment Upgrades

Physiological Versus Right Ventricular Outcome Trial Evaluated for Bradycardia Treatment Upgrades — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT06052475.

📅 23 Jun 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT06052475
Sponsor
Imperial College London
Start
2023-09-04
ClinicaliQ Trial Snapshot
  • Physiological Versus Right Ventricular Outcome Trial Evaluated for Bradycardia Treatment Upgrades — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT06052475.
  • What is being tested: Comparison of physiological pacing strategies versus traditional right ventricular (RV) pacing in patients undergoing first-time pacemaker implantation, specifically evaluating whether modern pacing approaches reduce RV pacing-induced cardiomyopathy.
  • Patient eligibility overview: Patients requiring first-time pacemaker implantation who have bradycardia indications, including those with only mildly impaired cardiac function who would traditionally receive standard RV pacing.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Guidelines for patients having first-time implants advocate that even when heart function is only mildly impaired, modern pacing approaches should be utilised to avoid the potentially damaging effects of RV pacing to preventing symptoms from pacing induced or worsened cardiomyopathy. However, once a traditional (RV) pacemaker is implanted, development of impaired heart function does not prompt a device upgrade. Even at the end of battery life, physicians simply replace it like-for-like. This trial tests whether such patients have better symptoms and quality of life if changed to a modern physiological…

Eligibility Snapshot
  • Patients with an RV pacemaker and LVEF 35-50% and a high burden of right ventricular pacing (>40%) who are clinically indicated for a cardiac resynchronisation therapy upgrade procedure and: 1. EF reduced by >5% of increase in LVESV by 10ml since implant 2. NT-proBNP >250ng/L in sinus rhythm 3. NT-proBNP > 750 Ng/L if AF 4. Left atrial volume index > 30ml/m2 5. Regular loop diuretics prescribed 6. Decline in daily patient activity by >1 hour per day since implant 7. Decrease in device measured thoracic impedance
  • Patient reported decline in functional class or exercise tolerance

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Finerenone for treating chronic heart failure with preserved or mildly reduced ejection fraction
Cardiology / Cardiovascular · 05 Aug 2026
Finerenone is recommended as an option for chronic heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) and can be initiated…
View guideline →
Guideline
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy
Cardiology / Cardiovascular · 30 Jul 2026
Patient selection: Consider aficamten for symptomatic obstructive hypertrophic cardiomyopathy patients who remain symptomatic despite optimised standard therapy (beta-blockers, non-dihydropyridine calcium channel blockers,…
View guideline →
Guideline
Artificial intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: early-use assessment
Cardiology / Cardiovascular · 19 May 2026
AI-assisted echocardiography can support faster preliminary analysis and reporting of echo images in heart failure patients, potentially reducing reporting delays and improving…
View guideline →
Guideline
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Cardiology / Cardiovascular · 07 May 2026
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part…
View guideline →
Guideline
2021 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronisation Therapy
Cardiology / Cardiovascular · 30 Mar 2026
Covers indications for cardiac pacing and cardiac resynchronization therapy (CRT) • Provides guidance on device selection, implantation techniques, and optimization • Addresses…
View guideline →
Guideline
Empagliflozin for Treating Chronic Heart Failure with Reduced Ejection Fraction (NICE TA773)
Cardiology / Cardiovascular · 27 Mar 2026
Initiate empagliflozin 10 mg once daily as add-on therapy to standard HFrEF treatment (ACE inhibitors, beta-blockers, and aldosterone antagonists) in adults with…
View guideline →